Viloxazine Layered Release Formulations for Sustained Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Developing extended release formulations of viloxazine is challenging due to its high therapeutic dose, weakly basic nature, and high in vivo clearance rate, which complicates achieving effective and sustained drug delivery.

Innovation Solution

The development of modified release formulations, including extended and pulsatile release formulations, utilizing a combination of extended release (XR), delayed release (DR), and immediate release (IR) components, with specific release rate controlling compounds and enteric coatings, to achieve high drug loads and controlled drug release profiles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If extended release formulations are developed for viloxazine, then sustained therapeutic levels and reduced dosing frequency are achieved, but formulation development becomes challenging due to high therapeutic dose, weakly basic nature, and high in vivo clearance rate

Engineering Contradiction:

Improveduration of therapeutic actionVSAvoidformulation development complexity

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The formulation is divided into multiple functional layers: an inner core containing viloxazine hydrochloride, a middle layer with release rate controlling compound, and an outer enteric coating layer. This segmentation allows independent optimization of each layer's function - drug loading, release rate control, and gastric protection - thereby achieving extended release while managing formulation complexity through modular design

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent utilizes pH-dependent solubility characteristics of the viloxazine hydrochloride and the enteric coating material to control drug release. By changing the environmental pH parameter from acidic (stomach) to neutral/alkaline (intestine), the formulation achieves delayed release and sustained therapeutic levels, addressing the challenge of high clearance rate through pH-triggered release mechanisms

Inventive Principle:

Principle #35Parameter changes

2Productivity

If high drug load formulations are used to reduce dosing frequency, then sustained therapeutic levels are achieved, but manufacturing precision and formulation stability become more difficult to control

Engineering Contradiction:

Improvedosing frequency reductionVSAvoidformulation precision

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The release rate controlling compound acts as an intermediary between the viloxazine hydrochloride core and the gastrointestinal environment. This intermediate layer regulates the diffusion and erosion rates, enabling high drug load (reducing dosing frequency) while maintaining precise control over release characteristics through the intermediary's controlled permeability and erosion properties

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The formulation employs composite material structure combining viloxazine hydrochloride (inner core), release rate controlling compound (middle layer), and enteric coating material (outer layer). Each material is selected for specific properties - the composite design enables high drug content while maintaining manufacturing precision through standardized coating techniques and controlled material interactions

Inventive Principle:

Principle #40Composite materials

3Reliability

If immediate release formulations are administered multiple times daily, then effective plasma concentrations are maintained, but undesirable side effects increase and patient compliance decreases

Engineering Contradiction:

Improveplasma concentration stabilityVSAvoidundesirable side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The extended release formulation provides continuous therapeutic action by maintaining stable plasma concentrations over 24 hours through controlled drug release. The multi-layer structure ensures continuous diffusion and erosion of the release rate controlling compound, eliminating the need for multiple daily doses and reducing side effects associated with frequent dosing while maintaining reliable plasma concentration stability

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulations provide sustained therapeutic levels of viloxazine for 4 to 24 hours, reduce undesirable side effects, and enhance bioavailability, while maintaining effective plasma concentrations comparable to immediate release formulations administered multiple times daily.

Implementation Method 1

an enteric coating layer that provides a delayed release profile

Methodology Applied

Scientific EffectpH-dependent dissolution:

Implementation Method 2

a release rate controlling compound that provides an extended release profile

Methodology Applied

Scientific EffectControlled dissolution:

Data Source

PatentUS20250222004A1Formulations of viloxazine

Publication Date: 2025.07.10 SUPERNUS PHARMACEUTICALS INC

AI summary

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.